The US Food and Drug Administration (FDA) is requiring that labels of general anesthetic and sedation drugs contain a new warning about their use in pregnant women during the 3rd trimester, and in children younger than 3 years. The action reflects concern about the effect that these agents may have on development of a child’s brain.
The FDA has been investigating the potential adverse effects of general anesthetic and sedation drugs on development of children’s brains since the first animal study on the topic in 1999. Recent human studies suggest that a single, relatively short exposure to general anesthetic and sedation drugs in infants or toddlers is unlikely to have negative effects on behavior or learning.
The agency is recommending that physicians balance the benefits of appropriate anesthesia against the potential risks in pregnant women and children, particularly for procedures that may last more than 3 hours or if multiple procedures are required in children younger than 3 years.
The drugs affected by the label change are deslurane, etomidate, halothane, isoflurane, ketamine, lorazepam injection, methohexital, midazolam injection and syrup, pentobarbital, propofol, and sevoflurane.
FDA drug safety communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women.
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Unraveling preeclampsia: Insights into heterogeneity and intravascular inflammation
April 22nd 2024A recent study delved into the intricate clusters of term preeclampsia, shedding light on its diverse manifestations and the pivotal role of intravascular inflammation, paving the way for improved classification and management strategies.
Read More